Results 11 to 20 of about 3,014 (182)

Prediction of the drug–drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib

CPT: Pharmacometrics & Systems Pharmacology, 2021
Erdafitinib is a potent oral pan‐fibroblast growth factor receptor inhibitor being developed as oncology drug for patients with alterations in the fibroblast growth factor receptor pathway.
Loeckie De Zwart, Jan Snoeys, Frank Jacobs, Lilian Y. Li, Italo Poggesi, Peter Verboven, Ivo Goris, Ellen Scheers, Inneke Wynant, Mario Monshouwer, Rao N. V. S. Mamidi   +10 more
doaj   +2 more sources

Ecofriendly, Simple, Fast and Sensitive UPLC-MS/MS Method for Determination of Erdafitinib, a Novel Tyrosine Kinase Inhibitor, in Plasma and Its Application to Metabolic Stability

Applied Sciences, 2022
Erdafitinib is an oral pan-fibroblast growth factor receptor (FGFR) inhibitor and has a potent antitumor activity against FGFR-aberrant malignancies.
Essam A. Ali, Muzaffar Iqbal, Gamal A. Mostafa, Mohamed R. Alhazani, Yousif A. Asiri   +4 more
doaj   +2 more sources

Erdafitinib-Induced Secondary Maculopathy

Journal of VitreoRetinal Diseases, 2022
Purpose: This work presents a case of secondary maculopathy associated with the use of erdafitinib (Balversa) for the management of bladder urothelial carcinoma with bony metastasis. Methods: A case report is presented. Results: A 58-year-old Hispanic man presented with blurry vision 3 weeks after starting erdafitinib for the management of bony ...
Brian Becker, Sophia El Hamichi, Aaron S. Gold, Timothy G. Murray   +3 more
core   +4 more sources

Erdafitinib diminishes LPS-mediated neuroinflammatory responses through NLRP3 in wild-type mice [PDF]

Frontiers in Pharmacology
IntroductionErdafitinib is an FDA-approved inhibitor of fibroblast growth factor receptor (FGFR) that is used clinically to treat metastatic urothelial cancer.
Hyun-ju Lee, Hyun-ju Lee, Se Ha Kim, Se Ha Kim, Tae-Mi Jung, Tae-Mi Jung, Yu-Jin Kim, Yu-Jin Kim, Chan-Hu Gu, Yoo Joo Jeong, Yoo Joo Jeong, Yoo Joo Jeong, Jeong-Heon Song, Hyang-Sook Hoe, Hyang-Sook Hoe, Hyang-Sook Hoe   +15 more
doaj   +2 more sources

Successful Treatment and Retreatment With Erdafitinib for a Patient With FGFR3-TACC3 Fusion Squamous NSCLC: A Case Report

JTO Clinical and Research Reports, 2023
FGFR3-TACC3 fusions have been identified in patients with multiple cancer types, and tumors with these alterations are potentially sensitive to selective FGFR inhibitors. However, there are no FGFR inhibitors approved by the U.S.
Chi Pham, BSc, Daenielle Lang, MD, Wade T. Iams, MD, MSCI   +2 more
doaj   +2 more sources

Erdafitinib-induced bilateral multifocal serous retinal detachments and severe dry eye related unilateral peripheral ulcerative keratitis in a patient with metastatic urothelial carcinoma

European Journal of Case Reports in Internal Medicine
Background: A case of bilateral multifocal serous retinal detachments and dry eye complicated with unilateral peripheral ulcerative keratitis (PUK) during erdafitinib therapy is described.
Mustafa Kayabaşı, İlknur Bilkay Görken, İsmet Durak, Aziz Karaoğlu, Ali Osman Saatci   +4 more
doaj   +2 more sources

Meta-analysis on the safety and efficacy of Erdafitinib in treating FGFR1–4 mutated solid tumors [PDF]

Frontiers in Oncology
ObjectiveThis article aims to analyze the safety and efficacy of Erdafitinib in the treatment of patients with advanced solid tumors harboring FGFR1–4 mutations.MethodsSearch for relevant articles in databases such as PubMed, Embase, The Cochrane Library,
Jiyu Huang, Zihan Wang, Fei Zhao, Adilai Aisa, Shengkai Tian, Siyuan Chen, Lianyi Peng, Xiaolu Yang, Jianxin He, Jianxin He, Yue Yang   +10 more
doaj   +2 more sources

FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma. [PDF]

Clin Cancer Res
On January 19, 2024, the FDA granted traditional approval to erdafitinib for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test,
Maguire WF, Chang E, Mulkey F, Hsu V, Wu H, Truong TM, Kappel D, Kraft J, Yu J, Gao X, Pierce WF, Rahman NA, Fiero MH, Amiri-Kordestani L, de Claro RA, Suzman DL.   +15 more
europepmc   +2 more sources

Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma. [PDF]

Clin Cancer Res
: Purpose: Up to 20% of patients with cholangiocarcinoma (CCA) harbor FGFR gene aberrations. Erdafitinib is approved for pretreated, locally advanced/metastatic urothelial carcinoma with susceptible FGFR3 alterations.
Pant S, Park JO, Su WC, Loriot Y, Carranza O, Corassa M, Doi T, Qin S, Tabernero J, Prenen H, Folprecht G, Winter H, Dal Molin GZ, Shen L, Qian J, Liao H, Thomas S, Sweiti H, Triantos S, Feng YH.   +19 more
europepmc   +2 more sources

Erdafitinib in Patients With Advanced Solid Tumors With <i>FGFR</i> Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts. [PDF]

JCO Precis Oncol
PURPOSE Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, is approved for second-line treatment of locally advanced or metastatic urothelial carcinoma ...
Carranza O, Pant S, Schuler M, Witt O, Geoerger B, Loriot Y, Farouk Sait S, Arnold D, Dal Molin GZ, Lugowska I, Winter H, Baldini C, Corassa M, Thomas S, Crow L, Xia Y, Triantos S, Sweiti H, Reardon DA.   +18 more
europepmc   +2 more sources